



# Neurohormonal modulation in pulmonary arterial hypertension

Eva L. Peters <sup>1,2</sup>, Harm Jan Bogaard<sup>1</sup>, Anton Vonk Noordegraaf <sup>1</sup> and Frances S. de Man<sup>1</sup>

<sup>1</sup>Dept of Pulmonology, Amsterdam UMC, Amsterdam, The Netherlands. <sup>2</sup>Dept of Physiology, Amsterdam UMC, Amsterdam, The Netherlands.

Corresponding author: Frances S. de Man ([fs.deman@amsterdamumc.nl](mailto:fs.deman@amsterdamumc.nl))



Shareable abstract (@ERSpublications)

**Better insight into neurohormonal changes throughout the development of pulmonary arterial hypertension and associated right heart failure is needed to allow efficacious intervention** <http://bit.ly/2NCV0nO>

**Cite this article as:** Peters EL, Bogaard HJ, Vonk Noordegraaf A, *et al.* Neurohormonal modulation in pulmonary arterial hypertension. *Eur Respir J* 2021; 58: 2004633 [DOI: 10.1183/13993003.04633-2020].

Copyright ©The authors 2021.

This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact [permissions@ersnet.org](mailto:permissions@ersnet.org)

Received: 24 Dec 2020  
Accepted: 13 March 2021

## Abstract

Pulmonary hypertension is a fatal condition of elevated pulmonary pressures, complicated by right heart failure. Pulmonary hypertension appears in various forms; one of those is pulmonary arterial hypertension (PAH) and is particularly characterised by progressive remodelling and obstruction of the smaller pulmonary vessels. Neurohormonal imbalance in PAH patients is associated with worse prognosis and survival. In this back-to-basics article on neurohormonal modulation in PAH, we provide an overview of the pharmacological and nonpharmacological strategies that have been tested pre-clinically and clinically. The benefit of neurohormonal modulation strategies in PAH patients has been limited by lack of insight into how the neurohormonal system is changed throughout the disease and difficulties in translation from animal models to human trials. We propose that longitudinal and individual assessments of neurohormonal status are required to improve the timing and specificity of neurohormonal modulation strategies. Ongoing developments in imaging techniques such as positron emission tomography may become helpful to determine neurohormonal status in PAH patients in different disease stages and optimise individual treatment responses.

## Introduction

Pulmonary hypertension is a fatal condition of elevated pulmonary pressures, complicated by right ventricular failure. Pulmonary hypertension is classified into five groups. Group 1 is pulmonary arterial hypertension (PAH), characterised by progressive remodelling and obstruction of the smaller pulmonary vessels [1]. The resulting decrease in arterial diameter can increase blood pressure in the pulmonary circulation up to five times the normal pressure [2]. The pulmonary circulation then changes from a low- to a high-pressure circulation, placing an increased load on the thin-walled right ventricle. This eventually leads to right ventricle failure and death [3, 4]. There is currently no cure for PAH and treatment options are limited.

One of the disease modifiers in all forms of pulmonary hypertension is neurohormonal imbalance, which has repeatedly been associated with poor clinical outcome and survival in PAH patients [5–7]. Therefore, many pharmacological and nonpharmacological interventions on the neurohormonal system have been investigated in pre-clinical and a few clinical studies [8]. Nevertheless, translation from pre-clinical to clinical studies is difficult and is often lacking.

Two recent reviews extensively described molecular pathways underlying the detrimental effects of neurohormonal activation [9] and pharmacological or invasive strategies targeting the neurohormonal system in PAH [8]. We wish to extend on this topic and thereby provide future directions for research into the neurohormonal system in PAH. In this back-to-basics article, we will therefore 1) recapitulate how the neurohormonal system ensures cardiovascular homeostasis; 2) describe how the neurohormonal system is changed in human PAH, both systemically and locally; 3) discuss how neurohormonal changes impact the




progression of PAH and right heart failure; and 4) give a comprehensive overview of the pre-clinical and clinical studies that intervene on the neurohormonal system in PAH.

Of note, neurohormonal changes likely play a role in all forms of pulmonary hypertension. Because most clinical data have been collected in PAH, this is the focus of our review. Moreover, other forms of pulmonary hypertension are characterised by frequent comorbidities (e.g. left heart failure or additional pulmonary diseases), complicating the view on the neurohormonal system. The neurohormonal changes and effects of interventions described hereafter are therefore focused on evidence obtained in PAH patients.

**Back to basics**

An important function of the neurohormonal system is to maintain cardiovascular homeostasis. Two pillars of the neurohormonal system are the autonomic nervous system (ANS) and the renin–angiotensin–aldosterone system (RAAS). The different components and functions of both systems are depicted in figure 1.

The ANS can be subdivided into two systems with opposite actions: the sympathetic nervous system (SNS) and the parasympathetic nervous system (PNS), as shown in figure 1a. The SNS possesses adrenergic synapses and is generally activated under (physiological) stress to prepare the body for action, while the PNS has cholinergic synapses and prevails during rest. However, both systems are continuously



**FIGURE 1** Short- and long-term control of blood pressure via neurohormonal signalling: a) autonomic nervous system (ANS) and b) renin–angiotensin–aldosterone system (RAAS). PNS: parasympathetic nervous system; SNS: sympathetic nervous system; Ang: angiotensin; ACE: angiotensin converting enzyme; CA: catecholamine; nAChR: nicotinic acetylcholine receptor; mAChR: muscarinic acetylcholine receptor; AR: adrenergic receptor; MR: mineralocorticoid receptor; AT<sub>1</sub>R: Ang II type 1 receptor; MAS-R: MAS receptor.

active at basal levels and the net physiological effect depends on the balance between SNS and PNS activity.

The ANS ensures short-term control of cardiovascular homeostasis. Blood pressure and arterial CO<sub>2</sub> levels are continuously monitored by baro- and chemoreceptors in the aortic arch and carotid sinus. When arterial blood pressure drops, baroreceptors are inactivated and baroreceptor-controlled inhibition of SNS is relieved. Meanwhile, PNS activity is suppressed, striking the balance towards the SNS. The SNS is also activated when increasing CO<sub>2</sub> levels in the blood are detected by chemoreceptors.

SNS activation then causes release of noradrenaline from synapses directly onto cardiac myocytes and blood vessels. In addition, sympathetic nerves stimulate the synthesis and release from the adrenal gland of adrenaline and noradrenaline [10] that reach the heart and lungs *via* the bloodstream. (Nor)adrenaline then binds to the  $\alpha$ - and  $\beta$ -adrenoreceptors. Increased signalling *via* adrenoreceptors and reduced signalling from the parasympathetic nicotinic and muscarinic acetylcholine receptors (nAChR and mAChR) result in a net increase in the rate and force of myocardial contraction. In addition, stimulation of  $\alpha$ -adrenoreceptors that are highly expressed in the vasculature causes vasoconstriction, so that arterial pressure is restored.

Like the ANS, the RAAS is subdivided into two counteractive systems: the classical and alternative RAAS system, as shown in figure 1b. The classical RAAS has been known for a long time, and involves angiotensin converting enzyme (ACE), angiotensin (Ang), Ang II type 1 receptor (AT<sub>1</sub>R), aldosterone and the mineralocorticoid receptor. The alternative RAAS system is less well-studied, and involves ACE2, Ang1-7, Ang1-9 and the MAS receptor.

The RAAS ensures long-term control of blood pressure and volume. When arterial blood pressure drops, perfusion pressure of the kidney is reduced. As a consequence, renin is released from the kidney into the blood and facilitates the conversion of angiotensinogen to Ang I. The latter is further converted to Ang II by ACE in the lungs [11]. Ang II acts as a strong vasoconstrictor *via* the AT<sub>1</sub>R but can also increase the rate and force of myocardial contractility [12]. Furthermore, Ang II promotes aldosterone release from the adrenal glands *via* the mineralocorticoid receptor to induce sodium and water retention in the kidneys and increase blood volume. However, aldosterone also directly acts on the heart, leading to cardiac hypertrophy and fibrosis [13]. These effects of aldosterone on the heart are independent from the increase in blood pressure. In the (pulmonary) vasculature, pathological levels of aldosterone are associated with oxidative stress and vascular inflammation [13].

In the opposing alternative RAAS pathway, Ang I is converted into Ang1-9 while Ang II is converted to Ang1-7, both by ACE2. Ang1-7 and Ang1-9 largely oppose the vascular effects of the classical RAAS pathway *via* the MAS receptor [14, 15]. Direct effects of Ang1-7 and Ang1-9 on the heart are unknown.

### **Neurohormonal systems interfere systemically and locally**

The ANS and RAAS do not operate in isolation. Several interactions have been demonstrated, both centrally and locally, and mostly studied in chronic heart failure patients or experimental heart failure. Interactions at the system level include SNS-induced renin release from the kidneys [16, 17] and central actions of Ang II in the brain. For example, it was shown that inhibition of classical RAAS signalling by ACE inhibitors or AT<sub>1</sub>R blockers increases PNS activity [18] and reduces SNS activity [19]. The latter happens also when AT<sub>1</sub>R blockade is applied to the brain only [20], suggesting that Ang II directly acts on the central nervous system. Furthermore, Ang II enhances chemoreceptor activation [21, 22] and inhibits baroreceptor reflex control of the heart rate [20, 23], both leading to increased SNS activity. By contrast, SNS activity can be reduced by the alternative RAAS pathway *via* inhibition of noradrenaline release in the hypothalamus [24].

Interactions between the ANS and RAAS occur locally as well. For instance, Ang II increases adrenergic signalling by potentiating the release of noradrenaline from sympathetic nerve terminals [20] and inhibits cardiac noradrenaline re-uptake [25]. In addition, gene expression of the AT<sub>1</sub>R in the heart is regulated by Ang II and the  $\beta$ <sub>1</sub>-adrenoreceptor [26, 27], suggesting that the balance of local SNS and classical RAAS determines gene expression of the AT<sub>1</sub>R in the heart. Cross-talk between  $\beta$ -adrenoreceptor and RAAS signalling has also been described in the pulmonary vasculature [6].

### **Systemic and local changes in the neurohormonal system in PAH patients**

#### ***Systemic changes in the ANS***

PAH has repeatedly been associated with a systemic increase in SNS activity. SNS activity, directly measured *via* muscle sympathetic nerve activity in a peripheral nerve, was increased in PAH patients [28, 29].

In addition, plasma levels of (nor)adrenaline were increased in PAH patients in most [30–33] but not all studies [34].

The SNS and PNS are connected in such a way that increasing SNS activity will cause decreased PNS activity. PNS activity can be indirectly assessed by indices of heart rate variability and heart rate recovery after exercise. As expected, both heart rate variability indices for PNS activity [28, 35, 36] and heart rate recovery [37, 38] were found to be reduced in PAH patients. The autonomic imbalance towards SNS activity and away from PNS activity is related to reduced exercise capacity [39, 40], worse New York Heart Association functional class [29, 41] and increased mortality in PAH [30, 32].

#### *Local changes in the ANS*

In PAH, the SNS is not only systemically activated, but also locally activated in the myocardium [33, 35, 42]. Important triggers for SNS activation are atrial and ventricular stretch:  $\beta$ -adrenoreceptor expression is downregulated specifically in the right ventricle but not in the left ventricle in PAH patients [43] and was related to ventricular wall stress [44]. The role of atrial stretch on SNS activation was shown in studies investigating balloon atrial septostomy. Although atrial septostomy was not designed to interfere with the neurohormonal system, it partially reduced muscle sympathetic nerve activity [45]. This reduction in muscle sympathetic nerve activity was related to the reduction in atrial pressure, suggesting that atrial stretch plays an additional role in SNS activation [45].

The acute increases in SNS are important to enhance the rate and force of cardiac contraction, and thus to enable the right ventricle to cope with the enhanced load. However, sustained cardiac SNS activation causes selective downregulation of  $\beta_1$ -adrenoreceptors and uncoupling of the remaining  $\beta$ -adrenoreceptors from downstream signalling [43]. Reduced  $\beta$ -adrenoreceptor expression and signalling impairs right ventricle function in at least two ways. First, although the contractility (end-systolic elastance) and force-generating capacity of right ventricle cardiomyocytes are enhanced in PAH patients [3], the loss of  $\beta$ -adrenoreceptor signalling reduces the right ventricle contractile reserve [43, 46]. Loss of contractile reserve results in arterioventricular uncoupling and acute right ventricle dilatation during exercise [47], and is associated with lower exercise capacity and reduced survival [48]. Second, reduced  $\beta$ -adrenoreceptor expression also plays an important role in impaired diastolic function in PAH. One of the downstream targets of the  $\beta$ -adrenoreceptor is protein kinase A (PKA), which regulates cardiomyocyte stiffness *via* phosphorylation of the giant sarcomeric protein titin [49]. Thus, reduced  $\beta$ -adrenoreceptor expression results in reduced PKA activity and PKA-mediated phosphorylation of titin, thereby increasing the stiffness of the right ventricle cardiomyocytes [50]. In experimental PAH, sustained adrenergic activation has further been linked to cardiac hypertrophy, fibrosis, apoptosis and reduced capillary density [51, 52].

Sustained adrenergic activation is also implicated in pulmonary vascular remodelling. Impaired  $\beta$ -adrenoreceptor signalling causes loss of nitric oxide production by pulmonary artery endothelial cells, resulting in pulmonary vasoconstriction [6]. This is further enhanced by direct adrenergic stimulation of pulmonary artery smooth muscle cells and collectively leads to chronic pulmonary vasoconstriction [6]. Moreover, continuous adrenergic stimulation causes pulmonary artery smooth muscle cell hypertrophy and proliferation [53, 54].

As opposed to what is known about local changes in the SNS, changes in counteractive PNS signalling have been reported in the right ventricle in only one study so far. DA SILVA GONÇALVES BOS *et al.* [36] showed that nAChR expression is increased in the right ventricle of PAH patients at the end stage and that there is likely reduced degradation of acetylcholine by acetylcholinesterase in the synaptic cleft. If and how the PNS is changed specifically in the lungs is largely unknown.

#### *Systemic changes in the RAAS*

Imbalances in RAAS activation have also been described in PAH. Plasma levels of Ang I and II are increased in PAH compared with healthy controls [55, 56]. However, Ang I and II levels are increased only in progressive PAH but not in stable PAH, and are associated with disease progression and mortality [57]. Plasma aldosterone concentrations are higher in PAH patients than in controls with unexplained dyspnoea but without PAH [58]. In a subgroup of treatment-naïve patients from this study, aldosterone levels correlated positively with pulmonary vascular resistance and negatively with cardiac output [58]. However, in a larger cohort of PAH patients, aldosterone concentration was not directly associated with cardiac output, 6-min walk distance (6MWD) or survival [59].

In addition to classical RAAS activation, alternative RAAS activation may be reduced in PAH. Decreased plasma levels of Ang1-7 and Ang1-9 in patients were reported in one study [56], while unchanged Ang1-7

levels were reported in another study [55]. In the latter study, a higher Ang II/Ang1-7 ratio indicated reduced conversion from Ang II to Ang1-7 by ACE2 [55]. Plasma concentrations of ACE2 are not lower in PAH patients compared with controls, but it was suggested that autoantibodies may reduce ACE2 activity [56]. Collectively, the balance within the RAAS seems to be in favour of classical RAAS activation, which is associated with worse disease progression and survival.

#### **Local changes in the RAAS**

In addition to systemic changes in classical RAAS signalling in PAH patients, local changes have been reported as well. The conversion from Ang I to Ang II by ACE happens predominantly in the lungs, where an overall decrease in pulmonary ACE activity was found [60]. This decrease may, however, be partly because of a reduced endothelial surface area. By contrast, ACE activity was increased in isolated pulmonary artery endothelial cells from PAH patients [57] and ACE expression was upregulated in smaller pulmonary vessels (intra-acinar arteries to capillaries) [61] and plexiform lesions [61, 62] of PAH patients. These findings imply that the formation of Ang II is increased locally in the PAH pulmonary vasculature. In addition, distal pulmonary arteries from PAH patients have increased AT<sub>1</sub>R expression [57]. Sustained Ang II exposure causes hypertrophy and proliferation of isolated patient pulmonary artery smooth muscle cells *via* AT<sub>1</sub>R signalling [57], and has been linked to vascular inflammation and fibrosis and impaired endothelial function [12].

In addition, local aldosterone synthesis is possible in the pulmonary vasculature [63]. Changes in aldosterone levels or mineralocorticoid receptor expression in the PAH lung have not been described. However, in experimental PAH, and in isolated human pulmonary artery smooth muscle cells and pulmonary artery endothelial cells, aldosterone has been associated with increased vascular remodelling [63–65].

Sustained classical RAAS activity also has unfavourable effects on the heart, including cardiomyocyte hypertrophy, fibrosis and conduction system disturbances [12]. The human heart possesses a local RAAS system, independent from but related to the circulating RAAS system [66]. Only one study has reported on local changes in RAAS activity in the heart in PAH [67]. As opposed to the lungs, AT<sub>1</sub>R expression was found to be decreased in the right ventricle, despite increased ACE expression and Ang II formation [67]. Local changes in cardiac aldosterone signalling have not been described in PAH.

Little is known about local changes in alternative RAAS activity. With renewed interest in ACE2, the entry point for the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus, it was recently shown that mRNA of soluble but not membrane-bound ACE2 is increased in explanted PAH lungs [68]. Although upregulated ACE2 can be considered beneficial in PAH, the implications of this shift towards soluble ACE2 for PAH patients are unknown. In the heart, ACE2 activity may be increased, as shown by increased formation of Ang1-7 from Ang II [69].


#### **Neurohormonal modulation strategies in PAH**

From the foregoing, it becomes clear that the neurohormonal system in PAH is out of balance both systemically and locally. Imbalances at both levels are associated with worse disease progression, survival or cardiac and vascular remodelling. Although increased SNS and classical RAAS activity are required to maintain cardiovascular homeostasis in case cardiac output drops, it is thought that chronic activation of the SNS and RAAS eventually becomes maladaptive. This may lead to a vicious circle of further cardiac deterioration and increased neurohormonal balance, exacerbated by progressive pulmonary vascular remodelling. Therefore, the neurohormonal systems have been the target of several experimental treatments. Treatment strategies can be divided into pharmacological and nonpharmacological approaches. An overview of both treatment strategies on the ANS and RAAS is given in figures 2 and 3, respectively.

#### **Pharmacological treatments**

The effects of pharmacological treatments targeting the different neurohormonal systems are summarised in table 1. Here, we will discuss the few approaches that have been tested in patients.


$\beta$ -blockers target the SNS and are the cornerstone of treatment of left ventricular failure, but current guidelines advise against the use of  $\beta$ -blockers in PAH [2]. A small pilot study demonstrated the safety of the nonselective  $\beta$ -blocker carvedilol in patients [79]. However, right ventricle function and 6MWD did not improve with carvedilol in a bigger randomised controlled trial [81], despite lower resting heart rate and increased  $\beta$ -adrenoreceptor expression. To prevent possible peripheral vasodilation and blunted exercise-induced skeletal muscle blood flow, the  $\beta_1$ -adrenoreceptor-selective  $\beta$ -blocker bisoprolol was tested [80]. In this study, a drop in cardiac index observed caused concern that cardiac function actually deteriorated [80]. Although no other indicators of progressive heart failure were seen, the lack of



**FIGURE 2** Targets of pharmacological and surgical interventions on the autonomic nervous system (ANS). PADN: pulmonary artery denervation; PA: pulmonary artery; PNS: parasympathetic nervous system; SNS: sympathetic nervous system; RAAS: renin-angiotensin-aldosterone system; RDN: renal denervation; ACh: acetylcholine; nAChR: nicotinic acetylcholine receptor; mAChR: muscarinic acetylcholine receptor; AR: adrenergic receptor.

improvements in cardiac function and 6MWD gave no indication to prescribe bisoprolol to PAH patients. Genetic variation in the  $\beta_1$ -adrenoreceptor can cause hypersensitivity to carvedilol but insensitivity to metoprolol and bisoprolol [116] and may cause different individual responses to  $\beta$ -blockers.

Pharmacological interventions on the classical RAAS include ACE inhibition,  $\text{AT}_1$  blockade and mineralocorticoid receptor antagonists. Clinical studies on ACE inhibition in pulmonary hypertension stem from the 1980s, when it was observed that captopril reduced both systemic and pulmonary vascular resistance in congestive heart failure [92]. Two early studies indicated that captopril reduced systemic but not pulmonary vascular resistance in PAH [91, 92]. By contrast, a significant decrease in pulmonary vascular resistance was found by IKRAM *et al.* [93] after only 4 days of captopril. In this small study of five patients, the two youngest patients showed clinical improvements during 3 weeks of maintenance treatment [93]. Collectively, these very small studies do not indicate a role for ACE inhibition by captopril in the treatment of PAH. In fact, the systemic vasodilatory effects of ACE inhibitors may exaggerate SNS and



**FIGURE 3** Targets of pharmacological and surgical interventions on the renin–angiotensin–aldosterone system (RAAS). Ang: angiotensin; ACE: angiotensin converting enzyme; ACEi: ACE inhibitor; MR: mineralocorticoid receptor; AT<sub>1</sub>R: Ang II type 1 receptor; MAS-R: MAS receptor.

classical RAAS activities. While no further trials have been conducted, ACE inhibition may still have benefit in subgroups of patients.

AT<sub>1</sub> blockade has not been tested clinically in PAH. Instead, two clinical studies investigated the use of losartan in pulmonary hypertension secondary to chronic obstructive pulmonary disease (COPD) [100] and in pulmonary hypertension secondary to lung disease or left ventricular failure [99]. Beneficial effects of losartan were observed after 8 weeks of treatment, including reduced mean pulmonary arterial pressure (mPAP) and increased exercise capacity [99]. However, in pulmonary hypertension secondary to COPD, losartan caused an early trend towards improvements in cardiac function and exercise capacity that was not maintained throughout 12 months of treatment [100]. Thus, AT<sub>1</sub> blockade by losartan may have short-term but not long-term effects in pulmonary hypertension patients.

Because of their diuretic action, mineralocorticoid receptor antagonists are used to manage symptoms of right ventricle failure in PAH. However, mineralocorticoid receptor antagonists may have additional effects on the heart and lungs. Two studies investigated the use of the mineralocorticoid receptor antagonist spironolactone in PAH. A retrospective analysis of patients using spironolactone while being enrolled in the ARIES-1 and -2 trial for the endothelin receptor antagonist ambrisentan [117] revealed that spironolactone use enhanced the benefits of ambrisentan on 6MWD and the severity of PAH [107]. However, patients using spironolactone had generally more severe PAH at baseline. Therefore, in these patients the therapeutic potential of ambrisentan may have been higher, which would falsely suggest an effect of spironolactone. The use of spironolactone alone has recently been studied in 42 group 1 PAH patients, 19 of whom had idiopathic PAH [106]. Although no effects of spironolactone were found on markers of fibrosis, exercise capacity, disease progression or cardiac function, the use of spironolactone was safe and well tolerated. An ongoing clinical trial (ClinicalTrials.gov: NCT01712620) aims to determine the clinical potential of spironolactone with longer treatment duration and earlier initiation.

TABLE 1 Effects of pharmacological treatments targeted at different neurohormonal signalling pathways in pre-clinical and clinical studies

Target system	Treatment strategy	Pre-clinical	Clinical
SNS	$\beta$ -blockers	Survival: $\uparrow$ [70] Disease progression: $\downarrow$ [71–73] Exercise capacity: $\uparrow$ [51] Cardiac function: $\uparrow$ [51, 73, 74], = [75] Cardiac remodelling: $\downarrow$ [51, 76], = [75] Vascular remodelling: $\downarrow$ [74, 77, 78], = [51]	Exercise capacity: = [79–81] Cardiac function: $\uparrow$ [79], $\downarrow$ [80]
PNS	Acetylcholinesterase inhibition	Disease progression: $\downarrow$ [36] Cardiac function: $\uparrow$ [36] Cardiac remodelling: $\downarrow$ [36] Vascular remodelling: $\downarrow$ [36]	
	Cholinergic agonists	Cardiac remodelling: $\downarrow$ [82] Vascular remodelling: $\downarrow$ [82]	
Classical RAAS	ACE inhibition	Disease progression: $\downarrow$ [83, 84] Cardiac function: $\downarrow$ [85], $\uparrow$ [84] Cardiac remodelling: $\downarrow$ [86–88], = [89] Vascular remodelling: $\downarrow$ [83–90], = [89]	Exercise capacity: = [91–93] Cardiac function: = [92, 93] mPAP/PVR: = [91, 92] (mPAP and PVR), $\downarrow$ [93] (mPAP)
	AT <sub>1</sub> blockers	Survival: $\uparrow$ [70] Disease progression: $\downarrow$ [57] Cardiac function: = [75] Cardiac remodelling: $\downarrow$ [94–96], = [70, 75, 97] Vascular remodelling: $\downarrow$ [57, 75, 95, 96], = [97, 98]	Exercise capacity: $\uparrow$ [99], = [100] Quality of life: = [100] mPAP/PVR: $\downarrow$ [99] (mPAP on echo)
	Mineralocorticoid receptor antagonists	Cardiac function: $\rightarrow$ [101–103*] Cardiac remodelling: $\downarrow$ [63, 65, 102], $\rightarrow$ [101, 103] Vascular remodelling: $\downarrow$ [63, 65, 101, 102, 104, 105], $\rightarrow$ [65]	Exercise capacity: $\rightarrow$ [106, 107] Cardiac function: $\rightarrow$ [106] mPAP: $\rightarrow$ [106]
Alternative RAAS	ACE2 activation	Disease progression: $\downarrow$ [108, 109] Cardiac function: $\uparrow$ [108, 109] Cardiac remodelling: $\downarrow$ [109–111] Vascular remodelling: $\downarrow$ [108–112]	Cardiac function: $\uparrow$ [55]
	Ang1-7 administration	Cardiac function: $\uparrow$ [109] Cardiac remodelling: $\downarrow$ [109, 113], = [114] Vascular remodelling: $\downarrow$ [109, 113], = [114]	
	Combined ACE2 and Ang1-7 administration	Cardiac function: $\uparrow$ [109], = [115] Cardiac remodelling: $\downarrow$ [109, 115] Vascular remodelling: $\downarrow$ [109, 115]	
	Ang1-9 administration	Cardiac remodelling: $\downarrow$ [14] Vascular remodelling: $\downarrow$ [14]	

$\uparrow$ : increased;  $\rightarrow$ : unchanged;  $\downarrow$ : decreased. SNS: sympathetic nervous system; PNS: parasympathetic nervous system; ACE: angiotensin converting enzyme; RAAS: renin–angiotensin–aldosterone system; mPAP: mean pulmonary arterial pressure; PVR: pulmonary vascular resistance; AT<sub>1</sub>: angiotensin II type 1 receptor. \*: combined with losartan.

Activating the counteractive alternative RAAS, instead of lowering classical RAAS activity, may also help to restore the balance within the RAAS. We are only beginning to recognise the role of the alternative RAAS system in the development of PAH. Therefore, to date, only one clinical pilot study exists, investigating the effects of recombinant human ACE2 administration in five patients with either idiopathic PAH or hereditary PAH [55]. Importantly, no safety concerns were raised and ACE2 was well tolerated. In addition, short-term improvements in pulmonary haemodynamics and inflammatory status were observed, paving the way for additional trials into ACE2 administration.

#### Nonpharmacological treatments

The results from pre-clinical and clinical studies into nonpharmacological strategies for neurohormonal modulation are summarised in table 2. Only pulmonary artery denervation (PADN) has been studied in PAH patients.

Pulmonary artery baroreceptor activation reflexively causes pulmonary vasoconstriction [132, 133], probably *via* adrenergic nerves [134]. This provides the rationale for PADN as a way to reverse pulmonary vasoconstriction. Indeed, an acute drop in mPAP was observed in 13 PAH patients who underwent



TABLE 2 Effects of nonpharmacological treatments targeted at different neurohormonal signalling pathways in pre-clinical and clinical studies

Target system	Treatment strategy	Pre-clinical	Clinical
SNS	Renal denervation	Survival: ↑ [118] Disease progression: ↓ [119] Cardiac function: ↑ [119, 120] Cardiac remodelling: ↓ [118–120] Vascular remodelling: ↓ [118–120]	
	Pulmonary artery denervation	Disease progression: ↓ [121] Exercise capacity: ↑ [121] Cardiac function: = [122], ↑ [121, 123–125] Cardiac remodelling: ↓ [121, 124, 125], = [122] Vascular remodelling: ↓ [121, 125, 126], = [122]	Survival: = [127] Disease progression: ↓ [127, 128] Exercise capacity: ↑ [127–130] Cardiac function: ↑ [127, 129, 130] mPAP/PVR: ↓ [127–130]
	Transection of the cervical sympathetic trunk	Cardiac function: ↑ [131] Cardiac remodelling: ↓ [131] Vascular remodelling: ↓ [131]	
PNS	Vagal nerve stimulation	Survival: ↑ [52] Cardiac function: ↑ [52] Cardiac remodelling: ↓ [52] Vascular remodelling: ↓ [52]	
Classical RAAS	NA	NA	NA
Alternative RAAS	NA	NA	NA

↑: increased; =: unchanged; ↓: decreased. SNS: sympathetic nervous system; PNS: parasympathetic nervous system; mPAP: mean pulmonary arterial pressure; PVR: pulmonary vascular resistance; RAAS: renin–angiotensin–aldosterone system; NA: not available.

PADN [127]. This reduction in mPAP was maintained during 3 months of follow-up, even while patients were completely withdrawn from PAH medication. In addition, progressive improvements in haemodynamics, 6MWD and clinical status were shown 6 months post-PADN. These improvements were maintained after up to 1 year of follow-up [129]. The improvements in haemodynamic status and 6MWD were recently confirmed in a multicentre open-label trial, although the benefit in that study was less dramatic [128]. Importantly, ROTHMAN *et al.* [128] showed highly variable individual responses in patients who underwent PADN. While mPAP and pulmonary vascular resistance were reduced on average, in three patients pulmonary vascular resistance actually increased. Interestingly, however, no acute reductions in mPAP were observed in this study or in another case report [130], suggesting that mechanisms apart from relieving the reflexive vasoconstriction may play a role.

One such mechanism may be a general reduction in SNS activity. Stretch of the pulmonary artery baroreceptors contributes to increased muscle sympathetic nerve activity in healthy individuals [135]. It is likely that this is the case in PAH patients too, given the extreme increase in pulmonary arterial pressure. In addition, pulmonary artery baroreceptor stimulation increases the arterial baroreceptor set point and threshold [136], causing inactivation of arterial baroreceptors and thus increased SNS activity. However, heart rate at 4 or 6 months follow-up post-PADN remained constant [128], suggesting that SNS activity was not reduced after the procedure.

#### Limitations for the use of neurohormonal modulation strategies in the clinic

So far, we have described systemic and local neurohormonal imbalance in PAH patients and strategies to restore them. Translational difficulties and lack of mechanistic insight into the development of neurohormonal imbalance in PAH patients have limited the use of neurohormonal modulation therapies.

Three-quarters of all studies described in this review were performed in various animal models of PAH, mostly rat, mouse and pig. However, promising results from  $\beta$ -blockers or ACE inhibitors seen in animal studies have not been translated to human trials. Obviously, the usefulness of these animal models can be disputed. First, commonly used rodent models resemble PAH in some but not all aspects. Experimental PAH usually develops over the course of several weeks instead of years, as is the case in human PAH. This potentially limits the development of compensatory mechanisms [137]. Second, clinical studies have always been conducted against a background of PAH-specific therapy, while animals received study medication only.

Clinical studies into neurohormonal modulation in PAH come with their own limitations. Importantly, the therapeutic window for any treatment is small in end-stage PAH and thus early intervention is usually

advocated [138]. However, it should be emphasised that neurohormonal changes are not solely maladaptive. In fact, acute changes in neurohormonal activity are vital in the maintenance of cardiovascular homeostasis and thus countering the neurohormonal systems may at times be detrimental. At some point in the progression of PAH, the persistent neurohormonal activation becomes maladaptive. During this phase neurohormonal modulation may be beneficial. Longitudinal data on neurohormonal changes in either right or left ventricular failure are scarce. Progressive increases in plasma levels of noradrenaline and renin have been described in chronic congestive heart failure [139], suggesting progressive neurohormonal imbalance. In addition, levels of noradrenaline, Ang II and aldosterone that are found in failing hearts have been shown to exert deleterious effects on the heart and vasculature, as reviewed elsewhere [140], suggesting dose-dependent effects of neurohormones. Thus, there seems to be an optimal treatment window to target the neurohormonal system, somewhere between the acute activation and chronic activation at pathological levels. It is therefore pivotal to obtain longitudinal data of neurohormonal activity, in combination with haemodynamic and right ventricle functional data.

Two important limitations have to be addressed that impede studies into neurohormonal changes over time. First, human tissue for investigation is hardly available and only from end-stage PAH. Therefore, it is less suitable to study longitudinal changes. Second, PAH is a rare disease and most clinical studies were able to include a few dozens of patients at best. This makes it difficult to reach sufficient statistical power, let alone to test subgroups of patients or different drug dosages and timing. The low number of patients is an important difference with studies into neurohormonal modulation in left ventricle failure, where neurohormonal modulation strategies have been implemented despite similar lack of insight into neurohormonal changes over time. This affects clinical studies in two ways. First, in left ventricle failure large cohorts of patients can be retrospectively analysed to identify factors that contribute to better or worse efficacy of neurohormonal modulation strategies. This is impossible in PAH. Second, small clinical studies with broad inclusion criteria hardly show any beneficial effects of neurohormonal modulation in PAH so far. Failure to enrol large numbers of patients requires diligent patient selection to prove smaller, yet clinically significant treatment effects.

Both the availability of human tissue for investigation and the limited numbers of patients in clinical trials will not change. Longitudinal assessment of neurohormonal changes could tell when and where neurohormonal derailment becomes evident in the course of the disease, and thereby help to select patients for specific neurohormonal modulation strategies. In addition, it will tell whether neurohormonal modulation strategies are timely and targeted as they are intended. Therefore, we advocate for the development, validation and use of noninvasive and minimally invasive tools to monitor neurohormonal changes in PAH. In the following section, we will discuss possible tools, in different stages of development, that may help to improve our understanding of the neurohormonal changes in PAH.

### **Strategies for longitudinal assessment of neurohormonal changes in PAH**

The gold standard to measure autonomic activity is to directly measure (para)sympathetic nerve trafficking by muscle microneurography, usually in a superficial skeletal muscle. Alternatively, determination of regional noradrenaline spillover allows for an organ-specific determination of SNS activation. Using microdialysis, local acetylcholine concentrations can be determined to measure PNS activity [141]. However, these measurements are all highly invasive and as such do not lend themselves for repeated testing. Instead, plasma (nor)adrenaline levels have been used to study SNS activation, but are not a reliable marker [29]. Alternatively,  $\beta$ -adrenoreceptor density in peripheral blood cells may serve as a marker of SNS (over)activation [142]. Traditionally, determination of  $\beta$ -adrenoreceptor density has relied on time-consuming ligand-binding assays. However, flow cytometric quantification of  $\beta$ -adrenoreceptor density was described recently [143], allowing for easy, high-throughput testing. Using this technique, it was shown that  $\beta$ -adrenoreceptor density is lower in blood cells in PAH patients compared with healthy controls [144] and is dose-dependently increased by the  $\beta$ -blocker carvedilol [81]. The changes in peripheral blood cells thus seem to mimic the changes seen in the heart. Further studies are needed to validate the use of flow cytometric quantification of  $\beta$ -adrenoreceptor expression as a marker of SNS in PAH patients.

Measuring PNS activity *via* plasma acetylcholine concentrations is not feasible due to high rates of degradation and clearance in the synaptic cleft [141]. Instead, plasma acetylcholinesterase activity may potentially serve as a biomarker for decreased PNS activity [145], but this requires validation in PAH patients.

Noninvasive indirect measures for PNS and SNS activities have been drawn from ECG parameters. There is natural variation in the time between consecutive heart beats, called heart rate variability. When

expressed in the frequency domain, high-frequency (HF), low-frequency (LF) and very-low-frequency spectral power can be distinguished [146]. The LF/HF ratio is commonly used to determine sympatho-vagal balance, assuming that LF power is generated by the SNS while HF power is generated by the PNS. However, this assumption does not hold true [146]. Not surprisingly, therefore, most studies do not find correlations between the LF/HF ratio and direct measures of SNS and PNS activities [141]. This is especially true in PAH where an inverse relation between the LF/HF ratio and muscle sympathetic nerve activity has been observed [28]. Furthermore, proper measurement and analysis of heart rate variability variables outside standardised laboratory settings is complicated [141]. Nevertheless, improved methods for the derivation of heartbeat-derived autonomic measures have been described [147] and the emergence of wearable devices, such as smartwatches and activity trackers, allows for ambulatory recordings in realistic settings.

Another noninvasive way to determine specifically PNS function is to measure heart rate recovery after maximal exercise. Heart rate recovery was shown to be reduced in PAH patients, and was related to chronotropic incompetence and clinical worsening [36–38, 148, 149]. Heart rate recovery could be easily and routinely assessed by cardiopulmonary exercise testing (CPET). Even easier, however, would be the use of heart rate recovery after the 6-min walk test (6MWT), which is performed more frequently in the clinic. It was shown in heart failure patients that the predictive value of heart rate recovery to predict survival is independent of whether the test is performed at maximal or submaximal intensity [150]. In PAH patients, it was shown that heart rate recovery after a 6MWT was even more predictive for clinical worsening than the test distance itself [38]. However, a direct comparison for the use of heart rate recovery from the 6MWT or maximal CPET has not been made either in heart failure or in PAH patients. One study showed that PAH patients exhibit relatively higher aerobic capacity during the 6MWT compared with CPET, despite lower heart rate, but did not compare the use of heart rate recovery as a marker for PNS activity [151]. It is worth investigating further whether these noninvasive measurements, potentially easily derived from ambulatory measurements or simple tests, could help to determine and monitor autonomic status in PAH patients.

Neurohormonal changes can also be studied using imaging techniques. Positron emission tomography (PET) may become an additional powerful tool to study neurohormonal activation in a clinical setting. Many PET tracers have now become available to study different aspects of the ANS, including pre-synaptic neurotransmitter recycling,  $\beta$ -adrenoreceptor density, PNS terminal nerves and mAChR expression [152].

PET tracers also exist to study RAAS activity, *via* ACE and AT<sub>1</sub>R expression [60, 153]. As ACE tracers usually accumulate in organs with high ACE expression, they are especially suitable to visualise ACE activity in the lungs [153]. Less tissue specific, but much quicker and cheaper, is the assessment of plasma levels and activity of the several RAAS components. As already mentioned, plasma levels of Ang I and II are increased in progressive but not in stable PAH [57]. In addition, plasma renin levels are an independent predictor of mortality in PAH [154].

Collectively, ongoing developments in heart rate variability algorithms and imaging techniques hold promise for the measurement and separation of neurohormonal activities. Together with plasma levels and CPET, they may provide tools for longitudinal assessment of the neurohormonal system and to study the interrelation between local neurohormonal systems in different organs.

### Conclusions

It is now clear that neurohormonal imbalance is involved in the development and progression of PAH. However, the neurohormonal system is vital for cardiovascular homeostasis. Thus, for successful clinical implementation, the timing and specificity of neurohormonal interventions needs to be improved. Because the number of patients available for clinical trials limits the use of subgroups, longitudinal assessment of neurohormonal activity is required. Noninvasive techniques such as imaging techniques may help to identify which patients may benefit from neurohormonal modulation and at which phase of disease progression.

**Acknowledgements:** The authors would like to thank Denielli da Silva Gonçalves Bos (Pulmonary Division – Heart Institute, University of São Paulo Medical School, São Paulo, Brazil) for discussion.

**Conflict of interest:** H.J. Bogaard reports grants and personal fees from Janssen, grants from Ferrer, personal fees from Novartis, outside the submitted work. A. Vonk Noordegraaf reports personal fees from Actelion and MSD,

personal fees and other (advisory board) from Bayer, other (advisory board) from Johnson & Johnson and MSD Morphogen-IX, outside the submitted work. F.S. de Man has nothing to disclose. E.L. Peters has nothing to disclose.

Support statement: H.J. Bogaard, A. Vonk Noordegraaf and F.S. de Man were supported by the Netherlands CardioVascular Research Initiative: the Dutch Heart Foundation, Dutch Federation of University Medical Centers, the Netherlands Organization for Health Research and Development, and the Royal Netherlands Academy of Sciences (CVON-2012-08 PHAEDRA, CVON-2018-29 PHAEDRA-IMPACT, CVON-2017-10 Dolphin-Genesis). H.J. Bogaard and A. Vonk Noordegraaf were supported by research grants from Actelion, GSK and Ferrer (Therabel). E.L. Peters, A. Vonk Noordegraaf and F.S. de Man were further supported by The Netherlands Organization for Scientific Research (NWO-VICI: 918.16.610, NWO-VIDI: 917.18.338). F.S. de Man was supported by the Dutch Heart Foundation Dekker senior post-doc grant (2018T059). Funding information for this article has been deposited with the Crossref Funder Registry.

## References

- 1 Farber HW, Loscalzo J. Pulmonary arterial hypertension. *N Engl J Med* 2004; 351: 1655–1665.
- 2 Galiè N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). *Eur Respir J* 2015; 46: 903–975.
- 3 Vonk Noordegraaf A, Westerhof BE, Westerhof N. The relationship between the right ventricle and its load in pulmonary hypertension. *J Am Coll Cardiol* 2017; 69: 236–243.
- 4 Vonk Noordegraaf A, Haddad F, Chin KM, et al. Right heart adaptation to pulmonary arterial hypertension: physiology and pathobiology. *J Am Coll Cardiol* 2013; 62: D22–D33.
- 5 De Man FS, Handoko ML, Guignabert C, et al. Neurohormonal axis in patients with pulmonary arterial hypertension: friend or foe? *Am J Respir Crit Care Med* 2013; 187: 14–19.
- 6 Maron BA, Leopold JA. Emerging concepts in the molecular basis of pulmonary arterial hypertension: part II: neurohormonal signaling contributes to the pulmonary vascular and right ventricular pathophenotype of pulmonary arterial hypertension. *Circulation* 2015; 131: 2079–2091.
- 7 Vaillancourt M, Chia P, Sarji S, et al. Autonomic nervous system involvement in pulmonary arterial hypertension. *Respir Res* 2017; 18: 201.
- 8 García-Lunar I, Pereda D, Ibanez B, et al. Neurohormonal modulation as a therapeutic target in pulmonary hypertension. *Cells* 2020; 9: 2521.
- 9 Maron BA, Leopold JA, Hemnes AR. Metabolic syndrome, neurohumoral modulation, and pulmonary arterial hypertension. *Br J Pharmacol* 2020; 177: 1457–1471.
- 10 Rhoades RA, Tanner GA. Medical Physiology. Philadelphia, Wolters Kluwer, 1995.
- 11 Ng KKF, Vane JR. Conversion of angiotensin I to angiotensin II. *Nature* 1967; 216: 762–766.
- 12 Mehta PK, Griendling KK. Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. *Am J Physiol Cell Physiol* 2007; 292: C82–C97.
- 13 Hermidorff MM, de Assis LVM, Isoldi MC. Genomic and rapid effects of aldosterone: what we know and do not know thus far. *Heart Fail Rev* 2017; 22: 65–89.
- 14 Cha SA, Park BM, Kim SH. Angiotensin-(1-9) ameliorates pulmonary arterial hypertension via angiotensin type II receptor. *Korean J Physiol Pharmacol* 2018; 22: 447–456.
- 15 Kostenis E, Milligan G, Christopoulos A, et al. G-protein-coupled receptor Mas is a physiological antagonist of the angiotensin II type 1 receptor. *Circulation* 2005; 111: 1806–1813.
- 16 Stella A, Zanchetti A. Functional role of renal afferents. *Physiol Rev* 1991; 71: 659–682.
- 17 Fong MW, Shavelle D, Weaver FA, et al. Renal denervation in heart failure. *Curr Hypertens Rep* 2015; 17: 17.
- 18 Binkley PF, Haas GJ, Starling RC, et al. Sustained augmentation of parasympathetic tone with angiotensin-converting enzyme inhibition in patients with congestive heart failure. *J Am Coll Cardiol* 1993; 21: 655–661.
- 19 Schlaich MP, Sobotka PA, Krum H, et al. Renal sympathetic-nerve ablation for uncontrolled hypertension. *N Engl J Med* 2009; 361: 932–934.
- 20 Wang Y, Seto SW, Gollledge J. Angiotensin II, sympathetic nerve activity and chronic heart failure. *Heart Fail Rev* 2014; 19: 187–198.
- 21 Schultz HD, Li YL, Ding Y. Arterial chemoreceptors and sympathetic nerve activity: implications for hypertension and heart failure. *Hypertension* 2007; 50: 6–13.
- 22 Allen AM. Angiotensin AT1 receptor-mediated excitation of rat carotid body chemoreceptor afferent activity. *J Physiol* 1998; 510: 773–781.
- 23 Goldsmith SR. Interactions between the sympathetic nervous system and the RAAS in heart failure. *Curr Heart Fail Rep* 2004; 1: 45–50.

- 24 Gironacci MM, Valera MS, Yujnovsky I, *et al.* Angiotensin-(1-7) inhibitory mechanism of norepinephrine release in hypertensive rats. *Hypertension* 2004; 44: 783–787.
- 25 Raasch W, Betge S, Dendorfer A, *et al.* Angiotensin converting enzyme inhibition improves cardiac neuronal uptake of noradrenaline in spontaneously hypertensive rats. *J Hypertens* 2001; 19: 1827–1833.
- 26 Katoh M, Egashira K, Takeshita A. Cardiac angiotensin II receptors are downregulated by chronic angiotensin II infusion in rats. *Jpn J Pharmacol* 2000; 84: 75–77.
- 27 Dockstader K, Nunley K, Karimpour-Fard A, *et al.* Temporal analysis of mRNA and miRNA expression in transgenic mice overexpressing Arg- and Gly389 polymorphic variants of the  $\beta$ 1-adrenergic receptor. *Physiol Genomics* 2011; 43: 1294–1306.
- 28 McGowan CL, Swiston JS, Notarius CF, *et al.* Discordance between microneurographic and heart-rate spectral indices of sympathetic activity in pulmonary arterial hypertension. *Heart* 2009; 95: 754–758.
- 29 Velez-Roa S, Ciarka A, Najem B, *et al.* Increased sympathetic nerve activity in pulmonary artery hypertension. *Circulation* 2004; 110: 1308–1312.
- 30 Nagaya N, Nishikimi T, Uematsu M, *et al.* Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. *Circulation* 2000; 102: 865–870.
- 31 Miyamoto S, Nagaya N, Satoh T, *et al.* Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing. *Am J Respir Crit Care Med* 2000; 161: 487–492.
- 32 Nootens M, Kaufmann E, Rector T, *et al.* Neurohormonal activation in patients with right ventricular failure from pulmonary hypertension: relation to hemodynamic variables and endothelin levels. *J Am Coll Cardiol* 1995; 26: 1581–1585.
- 33 Mak S, Witte KK, Al-Hesayen A, *et al.* Cardiac sympathetic activation in patients with pulmonary arterial hypertension. *Am J Physiol Regul Integr Comp Physiol* 2012; 302: 1153–1157.
- 34 Richards AM, Ikram H, Crozier IG, *et al.* Ambulatory pulmonary arterial pressure in primary pulmonary hypertension: variability, relation to systemic arterial pressure, and plasma catecholamines. *Br Heart J* 1990; 63: 103–108.
- 35 Wensel R, Jilek C, Dörr M, *et al.* Impaired cardiac autonomic control relates to disease severity in pulmonary hypertension. *Eur Respir J* 2009; 34: 895–901.
- 36 Da Silva Gonçalves Bos D, Van der Bruggen CEE, Kurakula K, *et al.* Contribution of impaired parasympathetic activity to right ventricular dysfunction and pulmonary vascular remodeling in pulmonary arterial hypertension. *Circulation* 2018; 137: 910–924.
- 37 Dimopoulos S, Anastasiou-Nana M, Katsaros F, *et al.* Impairment of autonomic nervous system activity in patients with pulmonary arterial hypertension: a case control study. *J Card Fail* 2009; 15: 882–889.
- 38 Minai OA, Gudavalli R, Mummadi S, *et al.* Heart rate recovery predicts clinical worsening in patients with pulmonary arterial hypertension. *Am J Respir Crit Care Med* 2012; 185: 400–408.
- 39 Billings CG, Hurdman JA, Condliffe R, *et al.* Incremental shuttle walk test distance and autonomic dysfunction predict survival in pulmonary arterial hypertension. *J Heart Lung Transplant* 2017; 36: 871–879.
- 40 Ciarka A, Doan V, Velez-Roa S, *et al.* Prognostic significance of sympathetic nervous system activation in pulmonary arterial hypertension. *Am J Respir Crit Care Med* 2010; 181: 1269–1275.
- 41 Bienias P, Cierzynski M, Kostrubiec M, *et al.* Functional class and type of pulmonary hypertension determinate severity. *Acta Cardiol* 2015; 70: 286–286.
- 42 Mercurio V, Pellegrino T, Bosso G, *et al.* Cardiac sympathetic dysfunction in pulmonary arterial hypertension: lesson from left-sided heart failure. *Pulm Circ* 2019; 9: 2045894019868620.
- 43 Bristow MR, Minobe W, Rasmussen R, *et al.* Beta-adrenergic neuroeffector abnormalities in the failing human heart are produced by local rather than systemic mechanisms. *J Clin Invest* 1992; 89: 803–815.
- 44 Rijnierse MT, Groeneveldt JA, Van Campen JSJA, *et al.* Bisoprolol therapy does not reduce right ventricular sympathetic activity in pulmonary arterial hypertension patients. *Pulm Circ* 2020; 10: 2045894019873548.
- 45 Ciarka A, Vachiéry J-L, Houssière A, *et al.* Atrial septostomy decreases sympathetic overactivity in pulmonary arterial hypertension. *Chest* 2007; 131: 1831–1837.
- 46 Sharma T, Lau EMT, Choudhary P, *et al.* Dobutamine stress for evaluation of right ventricular reserve in pulmonary arterial hypertension. *Eur Respir J* 2015; 45: 700–708.
- 47 Hsu S, Houston BA, Tampakakis E, *et al.* Right ventricular functional reserve in pulmonary arterial hypertension. *Circulation* 2016; 133: 2413–2422.
- 48 Grünig E, Tiede H, Enyimayew EO, *et al.* Assessment and prognostic relevance of right ventricular contractile reserve in patients with severe pulmonary hypertension. *Circulation* 2013; 128: 2005–2015.
- 49 Krüger M, Linke WA. Protein kinase-A phosphorylates titin in human heart muscle and reduces myofibrillar passive tension. *J Muscle Res Cell Motil* 2006; 27: 435–444.
- 50 Rain S, Andersen S, Najafi A, *et al.* Right ventricular myocardial stiffness in experimental pulmonary arterial hypertension. *Circ Heart Fail* 2016; 9: e002636.
- 51 Bogaard HJ, Natarajan R, Mizuno S, *et al.* Adrenergic receptor blockade reverses right heart remodeling and dysfunction in pulmonary hypertensive rats. *Am J Respir Crit Care Med* 2010; 182: 652–660.

- 52 Yoshida K, Saku K, Kamada K, *et al.* Electrical vagal nerve stimulation ameliorates pulmonary vascular remodeling and improves survival in rats with severe pulmonary arterial hypertension. *JACC Basic Transl Sci* 2018; 3: 657–671.
- 53 Luo J, Gu Y, Liu P, *et al.* Berberine attenuates pulmonary arterial hypertension *via* protein phosphatase 2A signaling pathway both *in vivo* and *in vitro*. *J Cell Physiol* 2018; 233: 9750–9762.
- 54 Luo Q, Wang X, Liu R, *et al.* alpha1A-adrenoceptor is involved in norepinephrine-induced proliferation of pulmonary artery smooth muscle cells *via* CaMKII signaling. *J Cell Biochem* 2019; 120: 9345–9355.
- 55 Hemnes AR, Rathinasabapathy A, Austin EA, *et al.* A potential therapeutic role for angiotensin-converting enzyme 2 in human pulmonary arterial hypertension. *Eur Respir J* 2018; 51: 1702638.
- 56 Sandoval J, Del Valle-Mondragón L, Masso F, *et al.* Angiotensin converting enzyme 2 and angiotensin (1-7) axis in pulmonary arterial hypertension. *Eur Respir J* 2020; 56: 2002416.
- 57 De Man FS, Tu L, Handoko ML, *et al.* Dysregulated renin–angiotensin–aldosterone system contributes to pulmonary arterial hypertension. *Am J Respir Crit Care Med* 2012; 186: 780–789.
- 58 Maron BA, Opatowsky AR, Landzberg MJ, *et al.* Plasma aldosterone levels are elevated in patients with pulmonary arterial hypertension in the absence of left ventricular heart failure: a pilot study. *Eur J Heart Fail* 2013; 15: 277–283.
- 59 Safdar Z, Thakur A, Singh S, *et al.* Circulating aldosterone levels and disease severity in pulmonary arterial hypertension HHS public access. *J Pulm Respir Med* 2015; 5: 295.
- 60 Qing F, McCarthy TJ, Markham J, *et al.* Pulmonary angiotensin-converting enzyme (ACE) binding and inhibition in humans: a positron emission tomography study. *Am J Respir Crit Care Med* 2000; 161: 2019–2025.
- 61 Orte C, Polak JM, Haworth SG, *et al.* Expression of pulmonary vascular angiotensin-converting enzyme in primary and secondary plexiform pulmonary hypertension. *J Pathol* 2000; 192: 379–384.
- 62 Schuster DP, Crouch EC, Parks WC, *et al.* Angiotensin converting enzyme expression in primary pulmonary hypertension. *Am J Respir Crit Care Med* 1996; 154: 1087–1091.
- 63 Maron BA, Zhang YY, White K, *et al.* Aldosterone inactivates the endothelin-B receptor *via* a cysteinyl thiol redox switch to decrease pulmonary endothelial nitric oxide levels and modulate pulmonary arterial hypertension. *Circulation* 2012; 126: 963–974.
- 64 Yamanaka R, Otsuka F, Nakamura K, *et al.* Involvement of the bone morphogenetic protein system in endothelin- and aldosterone-induced cell proliferation of pulmonary arterial smooth muscle cells isolated from human patients with pulmonary arterial hypertension. *Hypertens Res* 2010; 33: 435–445.
- 65 Preston IR, Sagliani KD, Warburton RR, *et al.* Mineralocorticoid receptor antagonism attenuates experimental pulmonary hypertension. *Am J Physiol Lung Cell Mol Physiol* 2013; 304: L678–L688.
- 66 Neri Serneri GG, Boddi M, Coppo M, *et al.* Evidence for the existence of a functional cardiac renin-angiotensin system in humans. *Circulation* 1996; 94: 1886–1893.
- 67 Zisman LS, Asano K, Dutcher DL, *et al.* Differential regulation of cardiac angiotensin converting enzyme binding sites and AT1 receptor density in the failing human heart. *Circulation* 1998; 98: 1735–1741.
- 68 Pérez-Vizcaíno F. Lung ACE2 and ADAM17 in pulmonary arterial hypertension: implications for COVID-19? *J Heart Lung Transplant* 2020; 39: 1167–1169.
- 69 Zisman LS, Keller RS, Weaver B, *et al.* Increased angiotensin-(1-7)-forming activity in failing human heart ventricles: evidence for upregulation of the angiotensin-converting enzyme homologue ACE2. *Circulation* 2003; 108: 1707–1712.
- 70 Usui S, Yao A, Hatano M, *et al.* Upregulated neurohumoral factors are associated with left ventricular remodeling and poor prognosis in rats with monocrotaline-induced pulmonary arterial hypertension. *Circ J* 2006; 70: 1208–1215.
- 71 Ishikawa M, Sato N, Asai K, *et al.* Effects of a pure alpha/beta-adrenergic receptor blocker on monocrotaline-induced pulmonary arterial hypertension with right ventricular hypertrophy in rats. *Circ J* 2009; 73: 2337–2341.
- 72 De Man FS, Handoko ML, Van Ballegoij JJMM, *et al.* Bisoprolol delays progression towards right heart failure in experimental pulmonary hypertension. *Circ Heart Fail* 2012; 5: 97–105.
- 73 Fowler ED, Drinkhill MJ, Norman R, *et al.* Beta1-adrenoceptor antagonist, metoprolol attenuates cardiac myocyte Ca<sup>2+</sup> handling dysfunction in rats with pulmonary artery hypertension. *J Mol Cell Cardiol* 2018; 120: 74–83.
- 74 Perros F, Ranchoux B, Izikki M, *et al.* Nebivolol for improving endothelial dysfunction, pulmonary vascular remodeling, and right heart function in pulmonary hypertension. *J Am Coll Cardiol* 2015; 65: 668–680.
- 75 Andersen S, Schultz JG, Andersen A, *et al.* Effects of bisoprolol and losartan treatment in the hypertrophic and failing right heart. *J Card Fail* 2014; 20: 864–873.
- 76 de Lima-Seolin BG, Colombo R, Bonetto JHP, *et al.* Bucindolol improves right ventricle function in rats with pulmonary arterial hypertension through the reversal of autonomic imbalance. *Eur J Pharmacol* 2017; 798: 57–65.
- 77 de Lima-Seolin BG, Hennemann MM, Fernandes RO, *et al.* Bucindolol attenuates the vascular remodeling of pulmonary arteries by modulating the expression of the endothelin-1 A receptor in rats with pulmonary arterial hypertension. *Biomed Pharmacother* 2018; 99: 704–714.

- 78 Fujio H, Nakamura K, Matsubara H, *et al.* Carvedilol inhibits proliferation of cultured pulmonary artery smooth muscle cells of patients with idiopathic pulmonary arterial hypertension. *J Cardiovasc Pharmacol* 2006; 47: 250–255.
- 79 Grinnan D, Bogaard HJ, Grizzard J, *et al.* Treatment of group I pulmonary arterial hypertension with carvedilol is safe. *Am J Respir Crit Care Med* 2014; 189: 1562–1564.
- 80 Van Campen JSJA, De Boer K, Van de Veerdonk MC, *et al.* Bisoprolol in idiopathic pulmonary arterial hypertension: an explorative study. *Eur Respir J* 2016; 48: 787–796.
- 81 Farha S, Saygin D, Park MM, *et al.* Pulmonary arterial hypertension treatment with carvedilol for heart failure: a randomized controlled trial. *JCI insight* 2017; 2: e95240.
- 82 Deng Y, Guo SL, Wei B, *et al.* Activation of nicotinic acetylcholine  $\alpha 7$  receptor attenuates progression of monocrotaline-induced pulmonary hypertension in rats by downregulating the NLRP3 inflammasome. *Front Pharmacol* 2019; 10: 128.
- 83 Nong Z, Stassen J-M, Moons L, *et al.* Inhibition of tissue angiotensin-converting enzyme with quinapril reduces hypoxic pulmonary hypertension and pulmonary vascular remodeling. *Circulation* 1996; 94: 1941–1947.
- 84 Ortiz LA, Champion HC, Lasky JA, *et al.* Enalapril protects mice from pulmonary hypertension by inhibiting TNF-mediated activation of NF- $\kappa$ B and AP-1. *Am J Physiol Lung Cell Mol Physiol* 2002; 282: L1209–L1221.
- 85 Abraham WT, Raynolds MV, Gottschall B, *et al.* Importance of angiotensin-converting enzyme in pulmonary hypertension. *Cardiology* 1995; 86: 9–15.
- 86 Morrell NW, Atochina EN, Morris KG, *et al.* Angiotensin converting enzyme expression is increased in small pulmonary arteries of rats with hypoxia-induced pulmonary hypertension. *J Clin Invest* 1995; 96: 1823–1833.
- 87 Kanno S, Wu YJL, Lee PC, *et al.* Angiotensin-converting enzyme inhibitor preserves p21 and endothelial nitric oxide synthase expression in monocrotaline-induced pulmonary arterial hypertension in rats. *Circulation* 2001; 104: 945–950.
- 88 Okada K, Bernstein ML, Zhang W, *et al.* Angiotensin-converting enzyme inhibition delays pulmonary vascular neointimal formation. *Am J Respir Crit Care Med* 1998; 158: 939–950.
- 89 Van Suylen RJ, Smits JFM, Daemen MJAP. Pulmonary artery remodeling differs in hypoxia- and monocrotaline-induced pulmonary hypertension. *Am J Respir Crit Care Med* 1998; 157: 1423–1428.
- 90 Baybutt R, Herndon B, Umbehr J, *et al.* Effects on cytokines and histology by treatment with the ACE inhibitor captopril and the antioxidant retinoic acid in the monocrotaline model of experimentally induced lung fibrosis. *Curr Pharm Des* 2007; 13: 1327–1333.
- 91 Rich S, Martinez J, Lam W, *et al.* Captopril as treatment for patients with pulmonary hypertension. Problem of variability in assessing chronic drug treatment. *Br Heart J* 1982; 48: 272–277.
- 92 Leier CV, Bambach B, Nelson S. Captopril in primary pulmonary hypertension. *Circulation* 1983; 67: 155–161.
- 93 Ikram H, Maslowski AH, Nicholls MG, *et al.* Haemodynamic and hormonal effects of captopril in primary pulmonary hypertension. *Br Heart J* 1982; 48: 541–545.
- 94 Nakamoto T, Harasawa H, Akimoto K, *et al.* Effects of olmesartan medoxomil as an angiotensin II-receptor blocker in chronic hypoxic rats. *Eur J Pharmacol* 2005; 528: 43–51.
- 95 Xie L, Lin P, Xie H, *et al.* Effects of atorvastatin and losartan on monocrotaline-induced pulmonary artery remodeling in rats. *Clin Exp Hypertens* 2010; 32: 547–554.
- 96 Lu Y, Guo H, Sun Y, *et al.* Valsartan attenuates pulmonary hypertension *via* suppression of mitogen activated protein kinase signaling and matrix metalloproteinase expression in rodents. *Mol Med Rep* 2017; 16: 1360–1368.
- 97 Tanabe Y, Morikawa Y, Kato T, *et al.* Effects of olmesartan, an AT1 receptor antagonist, on hypoxia-induced activation of ERK1/2 and pro-inflammatory signals in the mouse lung. *Naunyn Schmiedebergs Arch Pharmacol* 2006; 374: 235–248.
- 98 Clements RT, Vang A, Fernandez-Nicolas A, *et al.* Treatment of pulmonary hypertension with angiotensin II receptor blocker and neprilysin inhibitor sacubitril/valsartan. *Circ Heart Fail* 2019; 12: e005819.
- 99 Bozbaş ŞS, Bozbaş H, Atar A, *et al.* Comparative effects of losartan and nifedipine therapy on exercise capacity, Doppler echocardiographic parameters and endothelin levels in patients with secondary pulmonary hypertension. *Anatol J Cardiol* 2010; 10: 43–49.
- 100 Morrell NW, Higham MA, Phillips PG, *et al.* Pilot study of losartan for pulmonary hypertension in chronic obstructive pulmonary disease. *Respir Res* 2005; 6: 88.
- 101 Boehm M, Arnold N, Braithwaite A, *et al.* Eplerenone attenuates pathological pulmonary vascular rather than right ventricular remodeling in pulmonary arterial hypertension. *BMC Pulm Med* 2018; 18: 41.
- 102 Maron BA, Oldham WM, Chan SY, *et al.* Upregulation of steroidogenic acute regulatory protein by hypoxia stimulates aldosterone synthesis in pulmonary artery endothelial cells to promote pulmonary vascular fibrosis. *Circulation* 2014; 130: 168–179.
- 103 Borgdorff MA, Bartelds B, Dickinson MG, *et al.* A cornerstone of heart failure treatment is not effective in experimental right ventricular failure. *Int J Cardiol* 2013; 169: 183–189.

- 104 Aghamohammadzadeh R, Zhang YY, Stephens TE, *et al.* Up-regulation of the mammalian target of rapamycin complex 1 subunit Raptor by aldosterone induces abnormal pulmonary artery smooth muscle cell survival patterns to promote pulmonary arterial hypertension. *FASEB J* 2016; 30: 2511–2527.
- 105 Wang Y, Zhong B, Wu Q, *et al.* Effect of aldosterone on senescence and proliferation inhibition of endothelial progenitor cells induced by sirtuin 1 (SIRT1) in pulmonary arterial hypertension. *Med Sci Monit* 2020; 26: e920678.
- 106 Safdar Z, Frost A, Basant A, *et al.* Spironolactone in pulmonary arterial hypertension: results of a cross-over study. *Pulm Circ* 2020; 10: 2045894019898030.
- 107 Maron BA, Waxman AB, Opatowsky AR, *et al.* Effectiveness of spironolactone plus ambrisentan for treatment of pulmonary arterial hypertension (from the [ARIES] Study 1 and 2 Trials). *Am J Cardiol* 2013; 112: 720–725.
- 108 Shenoy V, Gjymishka A, Jarajapu YP, *et al.* Diminazene attenuates pulmonary hypertension and improves angiogenic progenitor cell functions in experimental models. *Am J Respir Crit Care Med* 2013; 187: 648–657.
- 109 Shenoy V, Kwon KC, Rathinasabapathy A, *et al.* Oral delivery of angiotensin-converting enzyme 2 and angiotensin-(1-7) bioencapsulated in plant cells attenuates pulmonary hypertension. *Hypertension* 2014; 64: 1248–1259.
- 110 Yamazato Y, Ferreira AJ, Hong KH, *et al.* Prevention of pulmonary hypertension by angiotensin-converting enzyme 2 gene transfer. *Hypertension* 2009; 54: 365–371.
- 111 Ferreira AJ, Shenoy V, Yamazato Y, *et al.* Evidence for angiotensin-converting enzyme 2 as a therapeutic target for the prevention of pulmonary hypertension. *Am J Respir Crit Care Med* 2009; 179: 1048–1054.
- 112 Li G, Zhang H, Zhao L, *et al.* Angiotensin-converting enzyme 2 activation ameliorates pulmonary endothelial dysfunction in rats with pulmonary arterial hypertension through mediating phosphorylation of endothelial nitric oxide synthase. *J Am Soc Hypertens* 2017; 11: 842–852.
- 113 Chen L, Xiao J, Li Y, *et al.* Ang(1-7) might prevent the development of monocrotaline induced pulmonary arterial hypertension in rats. *Eur Rev Med Pharmacol Sci* 2011; 15: 1–7.
- 114 Breitling S, Krauszman A, Parihar R, *et al.* Dose-dependent, therapeutic potential of angiotensin-(1–7) for the treatment of pulmonary arterial hypertension. *Pulm Circ* 2015; 5: 649–657.
- 115 Daniell H, Mangu V, Yakubov B, *et al.* Investigational new drug enabling angiotensin oral-delivery studies to attenuate pulmonary hypertension. *Biomaterials* 2020; 233: 119750.
- 116 Rochais F, Vilardaga JP, Nikolaev VO, *et al.* Real-time optical recording of  $\beta$ 1-adrenergic receptor activation reveals supersensitivity of the Arg389 variant to carvedilol. *J Clin Invest* 2007; 117: 229–235.
- 117 Galiè N, Olschewski H, Oudiz RJ, *et al.* Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. *Circulation* 2008; 117: 3010–3019.
- 118 Liu Q, Song J, Lu D, *et al.* Effects of renal denervation on monocrotaline induced pulmonary remodeling. *Oncotarget* 2017; 8: 46846–46855.
- 119 Da Silva Gonçalves Bos D, Happé C, Schaliij I, *et al.* Renal denervation reduces pulmonary vascular remodeling and right ventricular diastolic stiffness in experimental pulmonary hypertension. *JACC Basic Transl Sci* 2017; 2: 22–35.
- 120 Qingyan Z, Xuejun J, Yanhong T, *et al.* Beneficial effects of renal denervation on pulmonary vascular remodeling in experimental pulmonary artery hypertension. *Rev Esp Cardiol (Engl Ed)* 2015; 68: 562–570.
- 121 Huang Y, Liu YW, Pan HZ, *et al.* Transthoracic pulmonary artery denervation for pulmonary arterial hypertension. *Arterioscler Thromb Vasc Biol* 2019; 39: 704–718.
- 122 Garcia-Lunar I, Pereda D, Santiago E, *et al.* Effect of pulmonary artery denervation in postcapillary pulmonary hypertension: results of a randomized controlled translational study. *Basic Res Cardiol* 2019; 114: 5.
- 123 Rothman AMK, Arnold ND, Chang W, *et al.* Pulmonary artery denervation reduces pulmonary artery pressure and induces histological changes in an acute porcine model of pulmonary hypertension. *Circ Cardiovasc Interv* 2015; 8: e002569.
- 124 Zhou L, Zhang J, Jiang X-M, *et al.* Pulmonary artery denervation attenuates pulmonary arterial remodeling in dogs with pulmonary arterial hypertension induced by dehydrogenized monocrotaline. *JACC Cardiovasc Interv* 2015; 8: 2013–2023.
- 125 Zhang H, Yu W, Zhang J, *et al.* Pulmonary artery denervation improves hemodynamics and cardiac function in pulmonary hypertension secondary to heart failure. *Pulm Circ* 2019; 9: 2045894018816297.
- 126 Liu C, Jiang X-M, Zhang J, *et al.* Pulmonary artery denervation improves pulmonary arterial hypertension induced right ventricular dysfunction by modulating the local renin-angiotensin-aldosterone system. *BMC Cardiovasc Disord* 2016; 16: 192.
- 127 Chen S-L, Zhang F-F, Xu J, *et al.* Pulmonary artery denervation to treat pulmonary arterial hypertension: the single-center, prospective, first-in-man PADN-1 study (first-in-man pulmonary artery denervation for treatment of pulmonary artery hypertension). *J Am Coll Cardiol* 2013; 62: 1092–1100.
- 128 Rothman AMK, Vachieri JL, Howard LS, *et al.* Intravascular ultrasound pulmonary artery denervation to treat pulmonary arterial hypertension (TROPHY1): multicenter, early feasibility study. *JACC Cardiovasc Interv* 2020; 13: 989–999.



- 129 Chen SL, Xie DJ, Zhang J, *et al.* Hemodynamic, functional, and clinical responses to pulmonary artery denervation in patients with pulmonary arterial hypertension of different causes: phase II results from the pulmonary artery denervation-1 study. *Circ Cardiovasc Interv* 2015; 8: e002837.
- 130 Fujisawa T, Kataoka M, Kawakami T, *et al.* Pulmonary artery denervation by determining targeted ablation sites for treatment of pulmonary arterial hypertension. *Circ Cardiovasc Interv* 2017; 10: e005812.
- 131 Zhao Y, Xiang R, Peng X, *et al.* Transection of the cervical sympathetic trunk inhibits the progression of pulmonary arterial hypertension via ERK-1/2 signalling. *Respir Res* 2019; 20: 121.
- 132 Osorio J, Russek M. Reflex changes on the pulmonary and systemic pressures elicited by stimulation of baroreceptors in the pulmonary artery. *Circ Res* 1962; 10: 664–667.
- 133 Juratsch CE, Emmanouilides GC, Thibeault DW, *et al.* Pulmonary arterial hypertension induced by distention of the main pulmonary artery in conscious newborn, young, and adult sheep. *Pediatr Res* 1980; 14: 1332–1338.
- 134 Juratsch CE, Jengo JA, Castagna J, *et al.* Experimental pulmonary hypertension produced by surgical and chemical denervation of the pulmonary vasculature. *Chest* 1980; 77: 525–530.
- 135 Simpson LL, Meah VL, Steele A, *et al.* Evidence for a physiological role of pulmonary arterial baroreceptors in sympathetic neural activation in healthy humans. *J Physiol* 2020; 598: 955–965.
- 136 Moore JP, Hainsworth R, Drinkhill MJ. Reflexes from pulmonary arterial baroreceptors in dogs: interaction with carotid sinus baroreceptors. *J Physiol* 2011; 589: 4041–4052.
- 137 Ryan J, Bloch K, Archer SL. Rodent models of pulmonary hypertension: harmonisation with the World Health Organisation’s categorisation of human PH. *Int J Clin Pract* 2011; 65: 15–34.
- 138 Rafikova O, Al Ghouleh I, Rafikov R. Focus on early events: pathogenesis of pulmonary arterial hypertension development. *Antioxid Redox Signal* 2019; 31: 933–953.
- 139 Francis GS, Rector TS, Cohn JN. Sequential neurohumoral measurements in patients with congestive heart failure. *Am Heart J* 1988; 116: 1464–1468.
- 140 Hartupee J, Mann DL. Neurohormonal activation in heart failure with reduced ejection fraction. *Nat Rev Cardiol* 2017; 14: 30–38.
- 141 De Geus E, Van Lien R, Neijts M, *et al.* Genetics of autonomic nervous system activity. In: Canli T, ed. *The Oxford Handbook of Molecular Psychology*. Oxford, Oxford University Press, 2015; pp. 357–390.
- 142 Brodde OE, Kretsch R, Ikezono K, *et al.* Human  $\beta$ -adrenoceptors: relation of myocardial and lymphocyte  $\beta$ -adrenoceptor density. *Science* 1986; 231: 1584–1585.
- 143 Saygin D, Wanner N, Rose JA, *et al.* Relative quantification of beta-adrenergic receptor in peripheral blood cells using flow cytometry. *Cytometry A* 2018; 93: 563–570.
- 144 Rose JA, Wanner N, Cheong HI, *et al.* Flow cytometric quantification of peripheral blood cell  $\beta$ -adrenergic receptor density and urinary endothelial cell-derived microparticles in pulmonary arterial hypertension. *PLoS One* 2016; 11: e0156940.
- 145 Brzezinski RY, Fisher E, Cohen N, *et al.* Total serum cholinesterase activity predicts hemodynamic changes during exercise and associates with cardiac troponin detection in a sex-dependent manner. *Mol Med* 2018; 24: 63.
- 146 Shaffer F, Ginsberg JP. An overview of heart rate variability metrics and norms. *Front Public Health* 2017; 5: 258.
- 147 Valenza G, Citi L, Saul JP, *et al.* Measures of sympathetic and parasympathetic autonomic outflow from heartbeat dynamics. *J Appl Physiol* 2018; 125: 19–39.
- 148 Parrella P, Campi G, Rodolico A, *et al.* Parasympathetic activity in pulmonary arterial hypertension: could a simple measure do the trick? *Eur Respir J* 2018; 52: Suppl. 62, PA3324.
- 149 Wu C, Guo J, Liu H, *et al.* The correlation of decreased heart rate recovery and chronotropic incompetence with exercise capacity in idiopathic pulmonary arterial hypertension patients. *Biomed Res Int* 2017; 2017: 3415401.
- 150 Cahalin LP, Forman DE, Chase P, *et al.* The prognostic significance of heart rate recovery is not dependent upon maximal effort in patients with heart failure. *Int J Cardiol* 2013; 168: 1496–1501.
- 151 Deboeck G, Niset G, Vachieri JL, *et al.* Physiological response to the six-minute walk test in pulmonary arterial hypertension. *Eur Respir J* 2005; 26: 667–672.
- 152 Boutagy NE, Sinusas AJ. Recent advances and clinical applications of PET cardiac autonomic nervous system imaging. *Curr Cardiol Rep* 2017; 19: 33.
- 153 Chen X, Werner RA, Javadi MS, *et al.* Radionuclide imaging of neurohormonal system of the heart. *Theranostics* 2015; 5: 545–558.
- 154 Plácido R, Cortez-Dias N, Robalo Martins S, *et al.* Prognostic stratification in pulmonary hypertension: a multi-biomarker approach. *Rev Port Cardiol* 2017; 36: 111–125.